Gout comorbidities: results from the Korean National Health and Nutrition Examination Survey.
Humans
Gout
/ epidemiology
Republic of Korea
/ epidemiology
Male
Female
Nutrition Surveys
Middle Aged
Adult
Comorbidity
Prevalence
Hypercholesterolemia
/ epidemiology
Metabolic Syndrome
/ epidemiology
Renal Insufficiency, Chronic
/ epidemiology
Hypertension
/ epidemiology
Aged
Diabetes Mellitus
/ epidemiology
Odds Ratio
Young Adult
Comorbidity
Gout
Journal
Advances in rheumatology (London, England)
ISSN: 2523-3106
Titre abrégé: Adv Rheumatol
Pays: England
ID NLM: 101734172
Informations de publication
Date de publication:
27 Sep 2024
27 Sep 2024
Historique:
received:
30
01
2024
accepted:
11
09
2024
medline:
28
9
2024
pubmed:
28
9
2024
entrez:
28
9
2024
Statut:
epublish
Résumé
Gout is associated with several comorbidities. This study aimed to evaluate the prevalence of comorbidities in the Korean adult population with gout and investigated the association of gout with these comorbidities. Data from 15,935 (weighted n = 39,049,167) participants aged 19 years and older in the Korean National Health and Nutrition Examination Survey from 2019 to 2021 were used for analysis. Weighted prevalence and odds ratios (OR) of comorbidities in individuals with gout were compared to a non-gout population. The weighted prevalence of gout was 2.1% (weighted n = 808,778). Among individuals with gout, 66.5% had metabolic syndrome, 54.9% had hypertension, 41.2% had hypercholesterolemia, 19.1% had diabetes, 13.5% had chronic kidney disease (CKD), 4.1% had myocardial infarction or angina, 3.8% had stroke, and 2.8% had rheumatoid arthritis (RA). After adjusting for socioeconomic and lifestyle characteristics, gout was independently associated with the increased prevalence of metabolic syndrome (male OR = 2.0, 95% confidence interval (CI): 1.5-2.8; female OR = 3.7, 95% CI: 1.5-9.2), hypercholesterolemia (male OR = 1.9, 95% CI: 1.4-2.5; female OR = 3.1, 95% CI: 1.3-7.5), CKD (male OR = 4.5, 95% CI: 2.7-7.3; female OR = 11.5, 95% CI: 4.1-32.1), and RA (male OR = 2.8, 95% CI: 1.1-7.1; female OR = 3.1, 95% CI: 1.1-8.7) compared to the non-gout population. Gout was associated with several comorbidities, including RA, in both males and females. These results suggest that the prevention and treatment of comorbidities at the individual level, carried out by clinicians, and knowledge of these comorbidities would help guide health policies for the Korean population.
Identifiants
pubmed: 39334489
doi: 10.1186/s42358-024-00413-8
pii: 10.1186/s42358-024-00413-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
76Subventions
Organisme : National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT)
ID : No. 2021R1G1A1094093
Organisme : Soonchunhyang University Research Fund
ID : Soonchunhyang University Research Fund
Informations de copyright
© 2024. The Author(s).
Références
Singh JA, Gaffo A. Gout epidemiology and comorbidities. Semin Arthritis Rheum. 2020;50(3):S11–6.
pubmed: 32620196
doi: 10.1016/j.semarthrit.2020.04.008
Shi Y, Mucsi AD, Ng G. Monosodium urate crystals in inflammation and immunity. Immunol Rev. 2010;233(1):203–17.
Gliozzi M, Malara N, Muscoli S, Mollace V. Treat Hyperuricemia. Int J Cardiol. 2016;213:23–7.
Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med. 2017;15(1):123.
pubmed: 28669352
pmcid: 5494879
doi: 10.1186/s12916-017-0890-9
Singh JA, Gaffo A. Gout epidemiology and comorbidities. Semin Arthritis Rheum. 2020;50(3S):S11–6.
pubmed: 32620196
doi: 10.1016/j.semarthrit.2020.04.008
Roughley MJ, Belcher J, Mallen CD, Roddy E. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. Arthritis Res Ther. 2015;17:1–12.
Karis E, Crittenden DB, Pillinger MH. Hyperuricemia, gout, and related comorbidities: cause and effect on a two-way street. South Med J. 2014;107(4):235–41.
pubmed: 24937517
doi: 10.1097/SMJ.0000000000000082
Rai SK, Aviña-Zubieta JA, McCormick N, De Vera MA, Shojania K, Sayre EC, et al. The rising prevalence and incidence of gout in British Columbia, Canada: population-based trends from 2000 to 2012. Semin Arthritis Rheum. 2017;46(4):451–6.
pubmed: 28040245
doi: 10.1016/j.semarthrit.2016.08.006
Trifirò G, Morabito P, Cavagna L, Ferrajolo C, Pecchioli S, Simonetti M, et al. Epidemiology of gout and hyperuricaemia in Italy during the years 2005–2009: a nationwide population-based study. Ann Rheum Dis. 2013;72(5):694–700.
Kim J-W, Kwak SG, Lee H, Kim S-K, Choe J-Y, Park S-H. Prevalence and incidence of gout in Korea: data from the national health claims database 2007–2015. Rheumatol Int. 2017;37(9):1499–506.
pubmed: 28676911
doi: 10.1007/s00296-017-3768-4
Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008. Am J Med. 2012;125(7):679–e871.
pubmed: 22626509
doi: 10.1016/j.amjmed.2011.09.033
Rho YH, Choi SJ, Lee YH, Ji JD, Choi KM, Baik SH, et al. The prevalence of metabolic syndrome in patients with gout: a multicenter study. J Korean Med Sci. 2005;20(6):1029–33.
pubmed: 16361817
pmcid: 2779304
doi: 10.3346/jkms.2005.20.6.1029
Jung JH, Song GG, Ji JD, Lee YH, Kim JH, Seo YH, et al. Metabolic syndrome: prevalence and risk factors in Korean gout patients. Korean J Intern Med. 2018;33(4):815–22.
pubmed: 27729624
doi: 10.3904/kjim.2016.062
Oh K, Kim Y, Kweon S, Kim S, Yun S, Park S, et al. Korea National Health and Nutrition Examination Survey, 20th anniversary: accomplishments and future directions. Epidemiol Health. 2021;43:e2021025.
pubmed: 33872484
pmcid: 8289475
doi: 10.4178/epih.e2021025
Kweon S, Kim Y, Jang MJ, Kim Y, Kim K, Choi S, et al. Data resource profile: the Korea National Health and Nutrition Examination Survey (KNHANES). Int J Epidemiol. 2014;43(1):69–77.
pubmed: 24585853
pmcid: 3937975
doi: 10.1093/ije/dyt228
Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735–52.
pubmed: 16157765
doi: 10.1161/CIRCULATIONAHA.105.169404
Lamb EJ, Tomson CRV, Roderick PJ. Estimating kidney function in adults using formulae. Ann Clin Biochem. 2005;42(5):321–45.
pubmed: 16168188
doi: 10.1258/0004563054889936
Tu F-Y, Lin G-T, Lee S-S, Tung Y-C, Tu H-P, Chiang H-C. Prevalence of gout with comorbidity aggregations in southern Taiwan. Joint Bone Spine. 2015;82(1):45–51.
pubmed: 25238950
doi: 10.1016/j.jbspin.2014.07.002
Koto R, Nakajima A, Horiuchi H, Yamanaka H. Real-world treatment of gout and asymptomatic hyperuricemia: a cross-sectional study of Japanese health insurance claims data. Mod Rheumatol. 2021;31(1):261–9.
pubmed: 32552370
doi: 10.1080/14397595.2020.1784556
Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005. Ann Rheum Dis. 2008;67(7):960–6.
pubmed: 17981913
doi: 10.1136/ard.2007.076232
Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout. Third Natl Health Nutr Examination Surv. 2007;57(1):109–15.
Jeong H, Moon JE, Jeon CH. Hyperuricemia is Associated with an increased prevalence of metabolic syndrome in a General Population and a decreased prevalence of diabetes in men. J Rheumatic Dis. 2020;27(4):247–60.
doi: 10.4078/jrd.2020.27.4.247
Lee J, Sparrow D, Vokonas PS, Landsberg L, Weiss ST. Uric acid and coronary heart disease risk: evidence for a role of uric acid in the obesity-insulin resistance syndrome. The normative aging study. Am J Epidemiol. 1995;142(3):288–94.
pubmed: 7631632
doi: 10.1093/oxfordjournals.aje.a117634
Rathmann W, Funkhouser E, Dyer AR, Roseman JM. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary artery Risk Development in Young adults. Ann Epidemiol. 1998;8(4):250–61.
pubmed: 9590604
doi: 10.1016/S1047-2797(97)00204-4
Quiñones Galvan A, Natali A, Baldi S, Frascerra S, Sanna G, Ciociaro D, et al. Effect of insulin on uric acid excretion in humans. Am J Physiol. 1995;268(1 Pt 1):E1–5.
pubmed: 7840165
Roubenoff R, Klag MJ, Mead LA, Liang K-Y, Seidler AJ, Hochberg MC. Incidence and risk factors for gout in White men. JAMA. 1991;266(21):3004–7.
pubmed: 1820473
doi: 10.1001/jama.1991.03470210072035
Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the Health professionals follow-up study. Arch Intern Med. 2005;165(7):742–8.
pubmed: 15824292
doi: 10.1001/archinte.165.7.742
Wang J, Qin T, Chen J, Li Y, Wang L, Huang H, et al. Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies. PLoS ONE. 2014;9(12):e114259.
pubmed: 25437867
pmcid: 4250178
doi: 10.1371/journal.pone.0114259
Seong-Kyu K. Interrelationship of uric acid, gout, and metabolic syndrome: Focus on Hypertension, Cardiovascular Disease, and insulin resistance. J Rheumatic Dis. 2018;25(1):19–27.
doi: 10.4078/jrd.2018.25.1.19
Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Ren Physiol. 2002;282(6):F991–7.
doi: 10.1152/ajprenal.00283.2001
Mallamaci F, Testa A, Leonardis D, Tripepi R, Pisano A, Spoto B, et al. A polymorphism in the major gene regulating serum uric acid associates with clinic SBP and the white-coat effect in a family-based study. J Hypertens. 2014;32(8):1621–8; discussion 8.
pubmed: 24805955
doi: 10.1097/HJH.0000000000000224
Beattie CJ, Fulton RL, Higgins P, Padmanabhan S, McCallum L, Walters MR, et al. Allopurinol initiation and change in blood pressure in older adults with hypertension. Hypertension. 2014;64(5):1102–7.
pubmed: 25135183
doi: 10.1161/HYPERTENSIONAHA.114.03953
Chen S-Y, Chen C-L, Shen M-L, Kamatani N. Trends in the manifestations of gout in Taiwan. Rheumatology. 2003;42(12):1529–33.
pubmed: 13130146
doi: 10.1093/rheumatology/keg422
Qiu L, Cheng X-Q, Wu J, Liu J-T, Xu T, Ding H-T, et al. Prevalence of hyperuricemia and its related risk factors in healthy adults from Northern and northeastern Chinese provinces. BMC Public Health. 2013;13(1):664.
pubmed: 23866159
pmcid: 3722003
doi: 10.1186/1471-2458-13-664
Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020;16(7):380–90.
pubmed: 32541923
doi: 10.1038/s41584-020-0441-1
Fang Y-J, Wu T-Y, Lin C-L, Su C-Y, Li J-R, Chung Y-L, et al. Effects of Urate-lowering therapy on risk of Hyperlipidemia in gout by a Population-based Cohort Study and on in vitro hepatic lipogenesis-related gene expression. Mediat Inflamm. 2020;2020:8890300.
doi: 10.1155/2020/8890300
Kuwabara M, Borghi C, Cicero AFG, Hisatome I, Niwa K, Ohno M, et al. Elevated serum uric acid increases risks for developing high LDL cholesterol and hypertriglyceridemia: a five-year cohort study in Japan. Int J Cardiol. 2018;261:183–8.
pubmed: 29551256
doi: 10.1016/j.ijcard.2018.03.045
Lanaspa MA, Sanchez-Lozada LG, Choi Y-J, Cicerchi C, Kanbay M, Roncal-Jimenez CA, et al. Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and-independent fatty liver. J Biol Chem. 2012;287(48):40732–44.
Choi Y-J, Shin H-S, Choi HS, Park J-W, Jo I, Oh E-S, et al. Uric acid induces fat accumulation via generation of endoplasmic reticulum stress and SREBP-1c activation in hepatocytes. Lab Invest. 2014;94(10):1114–25.
Wu J, Zhang Y-P, Qu Y, Jie L-G, Deng J-X, Yu Q-H. Efficacy of uric acid-lowering therapy on hypercholesterolemia and hypertriglyceridemia in gouty patients. Int J Rheum Dis. 2019;22(8):1445–51.
Roughley MJ, Belcher J, Mallen CD, Roddy E. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. Arthritis Res Therapy. 2015;17(1):90.
doi: 10.1186/s13075-015-0610-9
Dalbeth N, House ME, Horne A, Taylor WJ. Reduced creatinine clearance is associated with early development of subcutaneous tophi in people with gout. BMC Musculoskelet Disord. 2013;14:363.
pubmed: 24359261
pmcid: 3878111
doi: 10.1186/1471-2474-14-363
Krishnan E. Reduced glomerular function and prevalence of gout: NHANES 2009-10. PLoS ONE. 2012;7(11):e50046.
pubmed: 23209642
pmcid: 3507834
doi: 10.1371/journal.pone.0050046
Kazancioğlu R. Risk factors for chronic kidney disease: an update. Kidney Int Supplements. 2013;3(4):368–71.
doi: 10.1038/kisup.2013.79
Jin M, Yang F, Yang I, Yin Y, Luo JJ, Wang H, et al. Uric acid, hyperuricemia and vascular diseases. Front Biosci (Landmark Ed). 2012;17:656.
Maruyama Y, Kumagai T, Sugano N, Yoshida S, Ichida K, Uchida S. Effect of uric acid-lowering therapy on renal function in patients with chronic kidney disease: a systematic review and meta-analysis. Ren Replace Therapy. 2021;7(1):44.
doi: 10.1186/s41100-021-00363-7
Kannuthurai V, Gaffo A. Management of patients with gout and kidney disease: a review of available therapies and common missteps. Kidney360. 2023;4(9):e1332–40.
pubmed: 37526648
pmcid: 10550007
doi: 10.34067/KID.0000000000000221
Olaru L, Soong L, Dhillon S, Yacyshyn E. Coexistent rheumatoid arthritis and gout: a case series and review of the literature. Clin Rheumatol. 2017;36(12):2835–8.
pubmed: 29022182
doi: 10.1007/s10067-017-3856-6
Jebakumar AJ, Udayakumar PD, Crowson CS, Matteson EL. Occurrence of gout in rheumatoid arthritis: it does happen! A population-based study. Int J Clin Rheumtol. 2013;8(4):433–7.
pubmed: 24443656
pmcid: 3891477
doi: 10.2217/ijr.13.45
Shi Y, Mucsi AD, Ng G. Monosodium urate crystals in inflammation and immunity. Immunol Rev. 2010;233(1):203–17.
pubmed: 20193001
doi: 10.1111/j.0105-2896.2009.00851.x
Spiga R, Marini MA, Mancuso E, Di Fatta C, Fuoco A, Perticone F, et al. Uric acid is Associated with inflammatory biomarkers and induces inflammation Via activating the NF-κB signaling pathway in HepG2 cells. Arterioscler Thromb Vasc Biol. 2017;37(6):1241–9.
pubmed: 28408375
doi: 10.1161/ATVBAHA.117.309128
Wang Z, Wang W, Xiang T, Gong B, Xie J. Serum uric acid as a diagnostic biomarker for Rheumatoid Arthritis-Associated interstitial lung disease. Inflammation. 2022;45(4):1800–14.
pubmed: 35314903
doi: 10.1007/s10753-022-01661-w